Bayer is close to a deal to acquire Monsanto, and an announcement could come as early as late next week, sources told CNBC Friday.
European stocks closed higher on Wednesday, despite weak German industrial production numbers and as investors awaited economic data from the U.S.
European stocks seesawed in trade on Tuesday as oil prices slipped and poor U.S. service sector data pushed many markets down.
German drugmaker Bayer and Monsanto are closing in on a deal, with Monsanto telling Bayer that it is "close" on price, sources told CNBC Tuesday.
In light of the M&A news surrounding Monsanto and Bayer, Mark Phelps, CIO of concentrated global equities at Alliance Bernstein, explains why more mergers are on the horizon.
The German pharmaceutical group raised its takeover approach to Monsanto to $127.50 per share on Sept. 6. It may even go further, says BreakingViews.
CNBC and NBC NY found thousands of FDA safety reports where deaths were classified as less serious injuries and equipment malfunctions.
Allen & Co. represents Wal-Mart in the latest sign that smaller upstarts are challenging the big banks on merger deals.
Bayer surpassed second-quarter earnings expectations and raised its guidance for the year on strong gains in stroke prevention pill Xarelto.
John Rountree, managing partner of Novasecta, discusses earnings at Bayer and the company's progress in acquiring Monsanto.
European equities posted strong gains by Wednesday's close, as a rally in technology stocks and a slew of positive earnings helped boost sentiment.
U.S. stock-index futures rose on Wednesday as investors cheered better-than-expected earnings from Morgan Stanley.
Monsanto said a sweetened $125-per-share offer from chemicals group Bayer is "financially inadequate and insufficient to ensure deal certainty."
Boutique banks have increased their market share of M&A over big Wall Street firms year over year.
U.S. sovereign bond yields pared gains after gunfire was heard and jets were seen flying in the Turkish capital of Ankara.
U.S. stock indexes futures traded higher Friday after better-than-expected retail sales.
Even though Bayer sweetened the pot in its attempt to win Monsanto, analysts suggest the seed company's board is likely to reject the offer.
The good news first: it's likely getting better. Of course, that comes as big banks try to rebound from the bad news: it's been the worst start to a year, on a number of metrics, since the global financial crisis.
Boutique banks have taken more of traditional banks’ cherished revenue driver this year than in 2015.
Politicians and regulators out to prevent monopolies kill inversion deals put a big crimp in a key Wall Street business.